Insulet (NASDAQ:PODD) Upgraded to “Strong-Buy” by BidaskClub
Other analysts have also recently issued reports about the stock. ValuEngine cut shares of Virtu Financial from a hold rating to a sell rating in a research report on Tuesday, June 18th. JPMorgan Chase & Co. cut shares of Sogou from a neutral rating to an underweight rating and decreased their price target for the stock from $5.50 to $4.12 in a research report on Thursday, June 27th. Canaccord Genuity decreased their price target on shares of Jamieson Wellness from C$23.00 to C$20.00 in a research report on Monday, May 6th. UBS Group set a €110.00 ($127.91) price target on shares of Wacker Chemie and gave the stock a buy rating in a research report on Thursday, June 13th. Finally, Svb Leerink reaffirmed an outperform rating on shares of Stryker in a research report on Wednesday, July 10th. Five equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $113.45.
Shares of NASDAQ PODD opened at $119.68 on Friday. Insulet has a 52-week low of $70.80 and a 52-week high of $124.38. The company’s fifty day moving average is $116.33. The stock has a market cap of $7.18 billion, a PE ratio of 2,393.60 and a beta of 1.12. The company has a debt-to-equity ratio of 2.68, a current ratio of 4.36 and a quick ratio of 3.71.
In other Insulet news, COO Charles Alpuche sold 3,900 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $104.78, for a total value of $408,642.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Shacey Petrovic sold 895 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $113.00, for a total transaction of $101,135.00. Following the completion of the transaction, the insider now owns 95,559 shares in the company, valued at approximately $10,798,167. The disclosure for this sale can be found here. Insiders sold a total of 41,894 shares of company stock worth $4,524,025 in the last quarter. 3.50% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of PODD. Norges Bank acquired a new position in Insulet in the 4th quarter worth $53,604,000. William Blair Investment Management LLC lifted its holdings in Insulet by 15.7% in the 1st quarter. William Blair Investment Management LLC now owns 2,144,988 shares of the medical instruments supplier’s stock worth $203,967,000 after buying an additional 290,790 shares in the last quarter. Frontier Capital Management Co. LLC lifted its holdings in Insulet by 12.3% in the 1st quarter. Frontier Capital Management Co. LLC now owns 1,958,736 shares of the medical instruments supplier’s stock worth $186,256,000 after buying an additional 214,033 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Insulet by 17.6% in the 1st quarter. Artisan Partners Limited Partnership now owns 1,391,041 shares of the medical instruments supplier’s stock valued at $132,274,000 after purchasing an additional 207,780 shares in the last quarter. Finally, KAMES CAPITAL plc raised its stake in shares of Insulet by 22.7% in the 1st quarter. KAMES CAPITAL plc now owns 582,252 shares of the medical instruments supplier’s stock valued at $55,372,000 after purchasing an additional 107,828 shares in the last quarter.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Further Reading: Hedge Funds – Risk or Reward?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.